Targeted drug for hormone-positive, HER2-low metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 3 trial tests disitamab vedotin (a targeted drug) in people with hormone receptor–positive, HER2-low metastatic breast cancer that can’t be cured with surgery or radiation. It aims to see whether the drug can control the cancer better than current standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (age 18–70) and are female with metastatic breast cancer
- Your tumor tests show ER and/or PR are positive, and HER2 is “low”
- Your cancer can’t be cured with surgery or radiation, and you have measurable disease or bone-only lytic metastases
- You’ve already received endocrine (hormone) therapy, and you’re currently well enough for treatment
- Recent blood, liver, kidney, and heart test results are within allowed limits
- You have no recent major chemotherapy/radiation/immunotherapy and no major surgery right before starting
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two drug combinations for HER2-positive breast cancer that has spread. It tests a newer drug (Disitamab Vedotin + Pyrotinib) against a standard treatment (THP) as a first treatment option.
This trial tests a drug called Disitamab Vedotin, given directly into the bladder, for a type of early bladder cancer (high-risk NMIBC) that has a protein called HER2. It aims to see if this treatment can help avoid more radical surgery.
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
This trial tests a combination of two drugs (disitamab vedotin and toripalimab) followed by chemotherapy before surgery for people with a specific type of breast cancer that is hormone receptor-positive and HER2-low. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a combination of two targeted drugs (disitamab vedotin and sintilimab) along with radiation for HER2-positive stomach cancer that has stopped responding to standard treatments. The goal is to see if this combo can shrink tumors and help you live longer.
This trial tests a combination of two targeted drugs (Disitamab Vedotin and Pyrotinib) for people with HER2-positive early breast cancer. It aims to see if this treatment can improve outcomes before standard therapy.
Hear when a new HR Positive/HER2 Low Expression Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.